SARS-CoV-2 XpressBio Research Reagents

A White Paper on Serology

COVID-19

Outbreaks with a novel coronavirus disease COVID-19 is caused by the SARS-CoV-2 virus. The virus has shown to be very contagious and has caused a world wide pandemic in the spring of 2020. The SARS-CoV-2 virus is a single strand RNA virus with glycoprotein spikes on its surface.  The spike protein (S) contains the receptor-binding domain (RBD) which has affinity to the angiotensin-converting enzyme 2 (ACE2). The interaction between RBD and ACE2 mediates the fusion of the viral and cellular membranes starting the infection process. The S protein has two subunits, S1 and S2. S1 contains the RBD region and the S2 is associated with the membrane of the virus. The nucleoprotein (N) is an abundant protein associated with virus structure and replication.

SARS-CoV-2 Research Reagents

 

Microplates

Controls

Antigens

SARS-CoV-2 S1 & S2

Ref# SP864C COVID-19 SARS-CoV-2 S1/S2 Microplate.

The antigen is a mixture of recombinant SARS-CoV-2 Spike glycoprotein (S1) and SARS-CoV-2 Spike glycoprotein (S2).


Ref# SPC864 COVID-19 SARS-CoV-2 S1/S2 Positive Control (Mouse monoclonal) 

 

Ref# SNC864 COVID-19 Negative Control.

 

Ref# XCOV006 SARS-CoV-2 Recombinant Spike Glycoprotein (S1) produced in HEK293 cells. Sequence strain Wuhan-Hu-1, amino acids 1-674, SHFc-Tag.

Ref# XCOV007 SARS-CoV-2 Recombinant Spike Glycoprotein (S2) produced in HEK293 cells. Sequence strain Wuhan-Hu-1, amino acids 685-1211, SHFc-Tag.

SARS-CoV-2 NUCLEOPROTEIN

Ref# SP865C COVID-19 SARS-CoV-2 Nucleoprotein Microplate.

The antigen is a recombinant SARS-CoV-2 Nucleocapsid protein.


Ref# SPC865 COVID-19 SARS-CoV-2 Nucleoprotein Positive Control (Mouse monoclonal) 

 

Ref# SNC864 COVID-19 Negative Control.

 

Ref# XCOV002 SARS-CoV-2 Recombinant Nucleocapsid protein produced in E. coli, clone nCOVNA. N-protein, amino acids 1-419, His-Tag.

Ref# XCOV003 SARS-CoV-2 Recombinant Nucleocapsid protein produced in E. coli, clone nCOVNB.

N-protein, amino acids 1-419, Fusion protein.

SARS-CoV-2 RBD + M-Protein

Ref# SP866C COVID-19 SARS-CoV-2 RBD + M Protein Microplate

The antigen is a recombinant SARS-CoV-2 Fusion Protein RBD (234 aa) and M-Protein.


Ref# SPC866 COVID-19 SARS-CoV-2 RBD + M Protein Positive Control (Chimeric monoclonal antibody with Human constant IgG1 domain). 

 

Ref# SNC864 COVID-19 Negative Control.

 

Ref# XCOV001 SARS-CoV-2 Recombinant Fusion Protein, Receptor-Binding Domain (RBD) and M-Protein (Virion Surface Domain of Membrane Protein) produced in HEK293 cells. RBD protein, 234 amino acids, C-His-Tag.    

Human Coronavirus

Ref# SP867C HCoV-229E Microplate

The antigen is a recombinant nucleocapsid protein (359 aa).

 

Ref# SP868C HCoV-NL63 Microplate

The antigen is a recombinant nucleocapsid protein (aa 221-340).

 

 

Ref# SNC864  Negative Control.

 

Ref# XCOV008 HCoV-229E Recombinant nucleocapsid protein produced in E. coli. 359 aa, C-His-Tag

Ref# XCOV009 HCoV-NL63 Recombinant nucleocapsid protein produced in E. coli. Aa 221-340, C-His-Tag

A White Paper on Serology

The white paper describe assessment of sensitivity and specificity of a multi-plate antigen strategy by testing Non-Human Primates.

We would suggest testing the samples on the S1 and S2 spike plates first. If a sample is positive, the same sample could be tested on the nucleoprotein plate, RBD + M plate and the seasonal coronavirus plates. If the sample is positive on the spike plate and negative on the others, it would indicate that the sample has antibodies to the HEK vector or the Fc tag as the others are different vectors and tags. If the sample is positive on all, it could indicate a cross reaction to other coronavirus, otherwise it is a non-specific sera. 

Please Download the White Paper here

Other Reagents
Spike Fusion Protein
 in Vaccine and Pathogenesis Research
Other kits (Human)

Kits Human IgG COVID-19 : Until June 30 th

  • US$ 396 instead of US$ 495

Under Development

A recent study in nonhuman primates shows that the use of a recombinant spike fusion protein, S1Fc, on the virus, prevents infection by inhibiting the fusion of the virus to the host cell membrane.

In other words, this protein antigen is a highly immunogenic molecule and stimulates the production of high levels of neutralizing antibodies. The Researchers tested the immune resistance recombinant SARSCoV2 S1Fc fusion protein in mice, rabbits, and monkeys against SARSCOV2 as a potential vaccine candidate.

www.news-medical.net article

  1. Human ACE2 ELISA Kit (sandwich ELISA for quantitative detection of ACE2)

  2. COVID-19 Nucleoprotein Antigen detection ELISA Kit

COVID-19 Price list.

Products for Research Use Only. Please inquire about quantity discounts

EUROPE
+ 33 675 88 10 59
thierry.delvienne@xpressbio.com

USA

+ 1 301-228-2444
888-562-8914 toll free

 

FOLLOW US:

  • Twitter Classic
  • Facebook Classic
  • LinkedIn Classic

© 2014 by DRT Consulting and XpressBio

 

Photography Credit: XpressBio
 

1,2,NIAID, Luca Voipi, Kat Masback, Daniel Paquet, Kaibara87, Umberto Salvagnin, ctomcsak, ciamabue, Global Panorama, AJ Cann, Duncan Hull, PAHO-WHO, Maarten, Francesco Paroni Sterbini, Nick Saltmarsh, AJC1, Carolfv333, Bilz0r? Kohlasz21, Nevit Dilmen, Emma Farmer, Jawahar Swaminathan